CSIMarket Company Name, Ticker, Suppliers, else..
 
Tenax Therapeutics Inc   (NASDAQ: TENX)
Other Ticker:  
 
 
Price: $5.7100 $-0.14 -2.393%
Day's High: $5.91 Week Perf: 0.35 %
Day's Low: $ 5.70 30 Day Perf: 18.71 %
Volume (M): 5 52 Wk High: $ 27.33
Volume (M$): $ 26 52 Wk Avg: $5.60
Open: $5.91 52 Wk Low: $2.77



 Market Capitalization (Millions $) 121
 Shares Outstanding (Millions) 21
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) 87
 Capital Exp. (TTM) (Millions $) 0

Tenax Therapeutics Inc
Tenax Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of products for the critical care market. The company is focused on addressing the needs of patients suffering from diseases and conditions with significant unmet medical need. Tenax Therapeutics is committed to developing innovative therapies that improve patient outcomes and quality of life. The company's key product candidate is levosimendan, a calcium sensitizer and potassium channel activator, which is being developed for use in treating patients with pulmonary hypertension associated with heart failure and low cardiac output syndrome after cardiac surgery. Tenax Therapeutics aims to become a leader in the critical care market by developing effective and safe therapies that optimize patient care.


   Company Address: 101 Glen Lennox Drive Chapel Hill 27517 NC
   Company Phone Number: 855-2100   Stock Exchange / Ticker: NASDAQ TENX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INVA   -2.62%    
PBYI   -3.52%    
TEVA   -5.82%    
UTHR   -2.18%    
VRTX        0.44% 
VTRS        0.79% 
• View Complete Report
   



Tenax Therapeutics Inc

Tenax Therapeutics Inc. Impresses Investors with Strong First Quarter Performance in 2024

Investors in the stock market have been pleasantly surprised by the recent performance of Tenax Therapeutics Inc. During the reporting season from January to March 31, 2024, the company saw a significant increase in operating profit compared to the same period in 2023. With operating profit reaching $3.908326 million, investors are optimistic about the direction in which the company is heading.
One of the key indicators of a company's health is its ability to generate profits, and Tenax Therapeutics Inc has shown that it is on the right track. Despite not posting a net income of $3.799 million during the fiscal period, the company's operating earnings still saw a substantial improvement, up 153.88% from the previous year. This growth is a testament to the company's dedication to effectively managing its operations and striving for success.
Tenax Therapeutics Inc

Tenax Therapeutics Inc. Shines with Impressive Fourth Quarter Financial Performance2.

The recent financial results of Tenax Therapeutics Inc. have exceeded all expectations, with an impressive increase in operating surplus and net income. This remarkable performance showcases the company's strong financial health and its ability to compete more economically in the pharmaceutical industry.
The shareholders were pleasantly surprised by the company's operating surplus of $3.340937 million during the October to December 31, 2023 earnings cycle. This represents a significant improvement from the previous year, where the operating surplus was $2.554624 million. Additionally, Tenax Therapeutics Inc. saw a substantial increase in net income for the fourth quarter of 2023, reaching $3.226 million compared to $2.549 million in the same period of 2022.
Management Announcement

Tenax Therapeutics Expands Global Rights to Revolutionary Treatment for Pulmonary Hypertension

Published Tue, Feb 20 2024 1:30 PM UTC



In a major breakthrough for the field of cardiovascular and pulmonary medicine, Tenax Therapeutics, a Phase 3, development-stage pharmaceutical company, has announced a significant expansion of its global development, commercial, and intellectual property rights to a life-changing treatment known as levosimendan. This development holds immense promise for patients ...
Clinical Study

Tenax Therapeutics Launches Groundbreaking Phase 3 Study Evaluating Novel Treatment for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Published Thu, Feb 8 2024 1:01 AM UTC

In a major stride towards combatting the debilitating heart condition known as Heart Failure with Preserved Ejection Fraction (HFpEF), Tenax Therapeutics has successfully enrolled the first patient in their groundbreaking Phase 3 study. The clinical trial, named LEVEL, aims to evaluate the effectiveness of TNX-103, an oral medication based on levosimendan, in treating the as...
Shares

Tenax Therapeutics Executes Reverse Stock Split to Foster Cardiovascular Market Expansion

Published Fri, Dec 29 2023 1:30 PM UTC



Chapel Hill-based specialty pharmaceutical company Tenax Therapeutics, Inc. (Nasdaq: TENX) has recently announced a significant strategic move that will reshape its capital structure and potentially open new avenues for growth. The company is set to execute a reverse stock split at a ratio of 1-for-80, aimed at strengthening its position in addressing the unmet med...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com